Department of Anesthesiology and Pain Medicine, Nationwide Children's Hospital, Columbus, Ohio, U.S.A.
Department of Anesthesiology and Pain Medicine, The Ohio State University, Columbus, Ohio, U.S.A.
Laryngoscope. 2019 Dec;129(12):2775-2781. doi: 10.1002/lary.27760. Epub 2019 Feb 20.
OBJECTIVES/HYPOTHESIS: Oxymetazoline is an α-adrenergic agonist that is commonly used as a topical hemostatic agent in the operating room during ear, nose, and throat surgery. There are limited data on oxymetazoline pharmacokinetics in children who undergo general anesthesia. We assessed the hemodynamic effects and systemic absorption of topically applied oxymetazoline in children undergoing various nasal procedures.
Prospective trial.
Children ages 2 to 17 years undergoing functional endoscopic sinus surgery, turbinate resection, or adenoidectomy were enrolled. The surgeon placed oxymetazoline-soaked pledgets (1.5 mL of 0.05% solution) according to our usual clinical practice. Blood samples for oxymetazoline assay were drawn at 5, 10, 20, 45, 90, and 150 minutes, and hemodynamic data were recorded at 5-minute intervals. Data analysis included mixed-effects regression and population pharmacokinetic/pharmacodynamic modeling.
The analysis included 27 patients, age 7 ± 4 years, who received between 2 and 12 pledgets (3-18 mL) of oxymetazoline. Relative bioavailability compared to the spray formulation was 2.3 (95% confidence interval [CI]: 1.6-3.2), with slow absorption from the mucosal surface (absorption half-life 64 minutes; 95% CI: 44-90). Mean arterial pressure did not increase with oxymetazoline instillation at the observed oxymetazoline serum concentrations (0.04-7.6 μg/L).
Despite concerns regarding oxymetazoline administration to mucosal membranes, we found that hemodynamic changes were clinically negligible with our usual clinical use of pledgets soaked in oxymetazoline. Compared to data on oxymetazoline in spray formulation, bioavailability was increased twofold with pledgets, but systemic absorption was very slow, contributing to low serum concentrations and limited hemodynamic effects.
1b. Laryngoscope, 129:2775-2781, 2019.
目的/假设:羟甲唑啉是一种 α-肾上腺素能激动剂,在耳鼻喉手术中,通常用作手术室的局部止血剂。接受全身麻醉的儿童中,羟甲唑啉药代动力学的数据有限。我们评估了在接受各种鼻部手术的儿童中局部应用羟甲唑啉的血流动力学效应和全身吸收。
前瞻性试验。
招募年龄在 2 至 17 岁之间、行功能性内镜鼻窦手术、鼻甲切除术或腺样体切除术的儿童。外科医生根据我们的常规临床实践放置羟甲唑啉浸湿的药垫(1.5 毫升 0.05%溶液)。在 5、10、20、45、90 和 150 分钟时抽取羟甲唑啉检测血样,并在 5 分钟间隔记录血流动力学数据。数据分析包括混合效应回归和群体药代动力学/药效学建模。
分析纳入了 27 名年龄 7 ± 4 岁的患者,他们接受了 2 至 12 个(3-18 毫升)羟甲唑啉药垫。与喷雾制剂相比,相对生物利用度为 2.3(95%置信区间[CI]:1.6-3.2),从黏膜表面吸收缓慢(吸收半衰期 64 分钟;95%CI:44-90)。在观察到的羟甲唑啉血清浓度(0.04-7.6 μg/L)下,羟甲唑啉给药不会导致平均动脉压升高。
尽管有关于羟甲唑啉在黏膜上给药的担忧,但我们发现,在我们常用的羟甲唑啉药垫临床使用中,血流动力学变化在临床上可以忽略不计。与喷雾制剂中的羟甲唑啉数据相比,药垫的生物利用度增加了两倍,但全身吸收非常缓慢,导致血清浓度较低,对血流动力学的影响有限。
1b。喉镜,129:2775-2781,2019。